AAOS 2025: BMAC Augmentation of Allograft Anterior Cruciate Ligament Reconstruction Improves PROMs .
BMAC Augmentation of Allograft Anterior Cruciate Ligament Reconstruction Improves Patient Reported Outcomes in the Presence of Intra-Articular Pathology
Eighty-three patients undergoing ACL reconstruction with bone-tendon-bone allograft were randomized to receive either intra-graft BMAC (n=44) or no BMAC (n=39). The primary outcomes of interest were Tegner activity scores and IKDC scores at 9 months. Secondary outcomes included MRI-based signal intensity ratio (SIR) and graft volume. Outcomes were assessed at 3 and 9 months. Overall, the results of the study revealed no difference in Tegner or IKDC scores when all patients were considered. However, among patients with concurrent meniscus or cartilage pathology, the BMAC group had significantly higher IKDC scores at 9 months and significantly higher SIR at 3 months. These findings suggest that BMAC may enhance functional recovery in patients with additional intra-articular pathology.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
